GlaxoSmithKline plc (GSK) to Issue Quarterly Dividend of $0.49 on January 10th

GlaxoSmithKline plc (NYSE:GSK) declared a quarterly dividend on Thursday, November 1st, NASDAQ reports. Shareholders of record on Friday, November 16th will be given a dividend of 0.486 per share by the pharmaceutical company on Thursday, January 10th. This represents a $1.94 dividend on an annualized basis and a yield of 4.71%. The ex-dividend date is Thursday, November 15th. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.46.

GlaxoSmithKline has decreased its dividend payment by an average of 8.9% annually over the last three years. GlaxoSmithKline has a payout ratio of 66.0% indicating that its dividend is sufficiently covered by earnings. Analysts expect GlaxoSmithKline to earn $3.05 per share next year, which means the company should continue to be able to cover its $1.94 annual dividend with an expected future payout ratio of 63.6%.

NYSE GSK opened at $41.30 on Friday. GlaxoSmithKline has a 12 month low of $34.52 and a 12 month high of $42.36. The company has a debt-to-equity ratio of 6.66, a quick ratio of 0.63 and a current ratio of 0.95. The stock has a market capitalization of $101.21 billion, a price-to-earnings ratio of 14.34, a P/E/G ratio of 2.74 and a beta of 0.80.

GSK has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of GlaxoSmithKline from a “sell” rating to a “hold” rating in a research report on Tuesday, July 17th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research report on Friday, July 20th. Bank of America set a $40.00 target price on shares of GlaxoSmithKline and gave the company a “hold” rating in a research report on Wednesday, July 25th. Shore Capital raised shares of GlaxoSmithKline from a “hold” rating to a “buy” rating in a research report on Friday, July 27th. Finally, Deutsche Bank reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research report on Wednesday, August 1st. Eleven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. GlaxoSmithKline presently has an average rating of “Hold” and a consensus target price of $41.57.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Stock Observer and is owned by of Stock Observer. If you are accessing this report on another publication, it was illegally copied and republished in violation of U.S. & international copyright law. The original version of this report can be read at

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Further Reading: Market Capitalization – What it Means for Investors

Dividend History for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with's FREE daily email newsletter.

Leave a Reply